PUBLISHER: Grand View Research | PRODUCT CODE: 1529688
PUBLISHER: Grand View Research | PRODUCT CODE: 1529688
The global high and ultra-high-field nuclear magnetic resonance spectroscopy market size is expected to reach USD 1.03 billion by 2035, growing at a CAGR of 5.70% from 2024 to 2035, according to a new report by Grand View Research, Inc. The expansion of the market can be attributed to several factors, including increased funding and investment in biomedical research, the rising necessity for cost-effective generic medications, the broadening application, and its growing acceptance in medical diagnostics. Various regulatory agencies suggest it as a useful technique in pharmaceutical manufacturing.
According to an article published by the European Pharmaceutical Review in October 2020, regulatory agencies such as the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and the U.S. FDA have issued guidance regarding the polymorphism for developing new & generic drugs. The guidance by these regulatory bodies highlighted SSNMR spectroscopy as a technique to determine the presence of multiple polymorphic forms during the identification of polymorphism in drug substances & products.
Thus, such guidance increases awareness about the wide uses of techniques during the development of generic drugs or APIs, which is expected to boost the high and ultra-high-field nuclear magnetic resonance spectroscopy market in the coming decade. Furthermore, it is useful in biomedical research due to its applications in cancer and infectious disease research. According to an article published by Griffith University in February 2021, nuclear magnetic resonance is a robust technique to determine the 3D structure of molecules, such as glycans, proteins, and DNA molecules. Such applications in the biomedical field, coupled with increasing biomedical research, are anticipated to drive market growth over the forecast period.
In addition, several studies demonstrate promising results for using nuclear magnetic resonance in metabolomics diagnosis. For instance, a study published by Dove Press in March 2022 reported that serum metabolites can serve as potential diagnostic biomarkers for tumor metastasis. H-NMR was utilized in this study to investigate serum metabolic profiles in a mouse model of colorectal cancer with lung metastasis.
Moreover, major participants are collaborating and partnering for drug discovery & development, which is expected to drive high and ultra-high-field nuclear magnetic resonance spectroscopy market growth over the forecast period. For instance, in January 2022, Evotek partnered with Lilly for drug discovery in metabolic diseases. Hence, the growing focus of key players on drug discovery & development of generic drugs & APIs, coupled with the increasing use of nuclear magnetic resonance spectroscopy in drug development, is anticipated to drive market growth in the coming decade.